文献速递肝病消化道肿瘤与早癌

丙型肝炎肝硬化患者获得持续病毒学应答后的长期患者报告结局

Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-01-22

本研究前瞻性纳入854例经直接抗病毒药物(DAA)治疗获得SVR-12的HCV肝硬化患者,其中代偿期730例、失代偿期124例,每24周收集SF-36、CLDQ-HCV和WPAI-HCV量表。失代偿期患者基线PRO损害更重,获得SVR后代偿期患者PRO改善可持续至168周,失代偿期患者改善持续至少96周但2年后呈下降趋势,且失代偿期患者肝癌和死亡率更高。

要点

  • HCV肝硬化患者基线PRO损害严重,失代偿期较代偿期更显著
  • 获得SVR后代偿期患者PRO改善可持续至168周(3.5年)
  • 失代偿期患者PRO改善持续至少96周,但2年后呈下降趋势

核心结论

  • HCV肝硬化患者基线PRO损害严重,获得SVR后可获得可持续改善。
  • 失代偿期患者虽也有改善,但2年后呈下降趋势。

研究设计与样本

  • 前瞻性长期注册研究(clinicaltrials.gov #NCT02292706),纳入DAA治疗获得SVR-12的HCV肝硬化患者854例,其中代偿期730例、失代偿期124例。
  • 每24周使用SF-36v2、CLDQ-HCV和WPAI-HCV收集PRO。

主要发现

  • 失代偿期患者较代偿期患者基线PRO严重受损(平均-5%至-16%的PRO范围大小;20个研究PRO中16个p<.05)。
  • 获得SVR后,失代偿期患者20个PRO域中11个显著改善(+4%至+21%),代偿期患者20个PRO域中19个显著改善(+3%至+17%)。
  • 失代偿期患者肝癌和死亡率更高(P<.05)。
  • 代偿期患者PRO改善持续至注册随访168周(3.5年);失代偿期患者改善持续至少96周,但2年后呈下降趋势。

临床怎么用

  • 对HCV肝硬化患者应关注PRO评估,代偿期患者获得SVR后PRO可长期改善。
  • 失代偿期患者获得SVR后仍需监测PRO变化,警惕2年后下降趋势及肝癌发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Achieving sustained virologic response (SVR) among patients with hepatitis C virus (HCV) leads to patient reported outcome (PRO) improvement. We aimed to assess the long-term post-SVR PRO trends in HCV patients with cirrhosis. METHODS: Patients with HCV and cirrhosis treated in clinical trials with direct acting antiviral agents (DAAs) who achieved SVR-12 were prospectively enrolled in a long-term registry (clinicaltrials.gov #NCT02292706). PROs were collected every 24 weeks using the Short Form-36v2 (SF-36), CLDQ-HCV, and WPAI-HCV. RESULTS: Pre-treatment baseline data were available for 854 cirrhotic patients who achieved SVR after DAAs. Of these, 730 had compensated (CC) and 124 had decompensated cirrhosis (DCC) before treatment- patients with DCC reported severe impairment in their PROs in comparison to CC patients (by mean -5% to -16% of a PRO range size; p < .05 for 16 out of 20 studied PROs]. After achieving SVR and registry enrollment, significant PRO improvements were noted from pre-treatment levels in 11/20 domains for those with DCC (+4% to +21%) and 19/20 PRO domains in patients with CC (+3% to +17%). Patients with baseline DCC had higher rates of hepatocellular carcinoma and mortality (P < .05). In patients with CC, the PRO gains persisted up to 168 weeks (3.5 years) of registry follow-up. In patients with DCC, the improvements lasted for at least 96 weeks but a declining trend after year 2. CONCLUSIONS: Patients with HCV cirrhosis experience severe PRO impairment at baseline with sustainable improvement after SVR. Though those with DCC experience improvement, there is a decline after 2 years.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Racila A, Muir A, et al. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clin Gastroenterol Hepatol. 2021. PMID: 33493697. doi:10.1016/j.cgh.2021.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。